Drugs / Cofact
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT02074358 | Feb → Apr 2014 | — | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT05205863 | Nov 2021 → Aug 2022 | — | Prothya Biosolutions | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Cofact | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05205863 ↗ |
| Modality | Protein / enzyme biologic | “Cofact (4-Factor PCC)” NCT02074358 ↗ |
| Route | Intravenous | “a Cofact (4-Factor PCC) 50 IU/kg infusion for 30 min Intravenously” NCT02074358 ↗ |